Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, WEST PHARMACEUTICAL SERVICES, INC. reported revenue of $3.07B, up 6.3% year over year. Operating margin was 19.0% and net margin 16.1%, on a free-cash-flow margin of 15.3% with capital expenditure at 9.3% of revenue. Every figure is computed directly from WST's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3.07B | 19.0% | 16.1% |
| FY2024 | $2.89B | 19.7% | 17.0% |
| FY2023 | $2.95B | 22.9% | 20.1% |
| FY2022 | $2.89B | 25.4% | 20.3% |
| FY2021 | $2.83B | 26.6% | 23.4% |
How does WST compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.